
Construction begins on MSD’s $1bn biologics centre in Delaware, US
Merck & Co (MSD) has begun construction on a $1bn biologics centre of excellence, Merck Wilmington Biotech, in Delaware, US. The 470,000ft² facility is set to bolster the company’s biologics and therapy production, including antibody-drug conjugates ( …